CLOCK and cancer: Facing the challenges in the process of treating PADA that how we could precisely distinguish between the low- and high- risk cohorts and how the immune infiltrates crosstalk to cancer cells, we aim to develop an indicator of distinct prognostic outcomes, and investigate its association with immune function and therapeutic efficacy, hoping to incorporate the pharmacological modulation of circadian clock into future therapeutic strategies.